TransMedics Group’s (TMDX) Buy Rating Reiterated at TD Cowen

TD Cowen reiterated their buy rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report sent to investors on Tuesday morning,Benzinga reports. TD Cowen currently has a $120.00 price objective on the stock.

Other analysts have also issued reports about the stock. Stifel Nicolaus increased their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. UBS Group decreased their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 5th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. Finally, Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, TransMedics Group presently has an average rating of “Hold” and an average target price of $124.18.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $85.04 on Tuesday. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The company’s 50-day moving average price is $81.73 and its two-hundred day moving average price is $90.63. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The stock has a market cap of $2.94 billion, a PE ratio of 21.86 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 earnings per share. As a group, sell-side analysts anticipate that TransMedics Group will post 1.46 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC raised its position in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after buying an additional 83 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after buying an additional 88 shares in the last quarter. HighPoint Advisor Group LLC grew its position in TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after buying an additional 88 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares during the period. Finally, US Bancorp DE increased its stake in TransMedics Group by 24.2% during the third quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after acquiring an additional 104 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.